-
Something wrong with this record ?
Hemostatické postupy minimalizující úmrtnost při operacích s velkými krevními ztrátami
[Hemostatic strategies for minimizing mortality in surgery with major blood loss]
Johansson PI.
Language Czech Country Czech Republic
Document type Review
- MeSH
- General Surgery MeSH
- Blood Transfusion methods mortality MeSH
- Hemorrhage complications mortality therapy MeSH
- Humans MeSH
- Survival Rate MeSH
- Check Tag
- Humans MeSH
- Publication type
- Review MeSH
Continued hemorrhage remains a major contributor of mortality in massively transfused patients and controversy regarding their optimal management exists. This article reviews recent advances that impact the use and effectiveness of massive transfusion. RECENT FINDINGS: In the past 18 months, nine retrospective studies and three before and after studies have evaluated the implementation of massive transfusion protocols in massively transfused patients receiving more than 10 units of red blood cells (RBCs) within 24 h from arrival. All studies demonstrate that patients receiving a high fresh frozen plasma (FFP):RBC or platelet:RBC ratio have improved survival, with patients receiving both high FFP:RBC and platelet:RBC ratios exhibiting the highest survival rate. When whole blood thrombelastography is used to guide transfusion therapy in massively bleeding patients, an increase in FFP and platelet to RBC ratio is also seen, and this is associated with improved survival. This indicates that thrombelastography is better than conventional coagulation assays to monitor coagulopathy and predict transfusion requirements in massive bleeders. SUMMARY: Implementation of more aggressive hemostatic resuscitation strategies in massively bleeding patients seems reasonable, and optimally, thrombelastography should be used to monitor coagulopathy and guide FFP and platelet transfusions.
Hemostatic strategies for minimizing mortality in surgery with major blood loss
Lit.: 46
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10004418
- 003
- CZ-PrNML
- 005
- 20111210160435.0
- 008
- 100222s2009 xr e cze||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a cze $b eng
- 044 __
- $a xr
- 100 1_
- $a Johansson, Par I.
- 245 10
- $a Hemostatické postupy minimalizující úmrtnost při operacích s velkými krevními ztrátami / $c Johansson PI.
- 246 11
- $a Hemostatic strategies for minimizing mortality in surgery with major blood loss
- 314 __
- $a Regional Blood Bank, Section for Transfusion Service, Rigshospitalet, University of Copenhagen, Copenhagen per.johansson@rh.regionh.dk
- 504 __
- $a Lit.: 46
- 520 9_
- $a Continued hemorrhage remains a major contributor of mortality in massively transfused patients and controversy regarding their optimal management exists. This article reviews recent advances that impact the use and effectiveness of massive transfusion. RECENT FINDINGS: In the past 18 months, nine retrospective studies and three before and after studies have evaluated the implementation of massive transfusion protocols in massively transfused patients receiving more than 10 units of red blood cells (RBCs) within 24 h from arrival. All studies demonstrate that patients receiving a high fresh frozen plasma (FFP):RBC or platelet:RBC ratio have improved survival, with patients receiving both high FFP:RBC and platelet:RBC ratios exhibiting the highest survival rate. When whole blood thrombelastography is used to guide transfusion therapy in massively bleeding patients, an increase in FFP and platelet to RBC ratio is also seen, and this is associated with improved survival. This indicates that thrombelastography is better than conventional coagulation assays to monitor coagulopathy and predict transfusion requirements in massive bleeders. SUMMARY: Implementation of more aggressive hemostatic resuscitation strategies in massively bleeding patients seems reasonable, and optimally, thrombelastography should be used to monitor coagulopathy and guide FFP and platelet transfusions.
- 650 _2
- $a krevní transfuze $x metody $x mortalita $7 D001803
- 650 _2
- $a chirurgie $7 D013502
- 650 _2
- $a krvácení $x komplikace $x mortalita $x terapie $7 D006470
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a míra přežití $7 D015996
- 655 _2
- $a přehledy $7 D016454
- 773 0_
- $w MED00164059 $t Current opinion in hematology $g Roč. 1, č. 4 (2009), s. 81-85 $x 1803-683X
- 910 __
- $a ABA008 $b B 2586 $c 316 $y 8
- 990 __
- $a 20100222113340 $b ABA008
- 991 __
- $a 20100222120537 $b ABA008
- 999 __
- $a ok $b bmc $g 713839 $s 576787
- BAS __
- $a 3
- BMC __
- $a 2009 $b 1 $c 4 $d 81-85 $i 1803-683X $m Current Opinion in Hematology $x MED00164059
- LZP __
- $a 2010-03/mkme